This antibody is primarily used in therapeutic research targeting inflammatory and metabolic diseases. It modulates the activity of PGLYRP1 (Peptidoglycan Recognition Protein 1), a protein involved in innate immune responses, making it a candidate for treating conditions such as type 2 diabetes, obesity-related inflammation, and other chronic inflammatory disorders. By neutralizing or inhibiting PGLYRP1, the antibody helps reduce low-grade inflammation associated with insulin resistance. It is also employed in preclinical studies to validate PGLYRP1 as a drug target and to assess downstream effects on immune cell activation and metabolic pathways. Additionally, this reference antibody serves as a tool for assay development, target engagement studies, and biomarker identification in relevant disease models.